Objective: Radical prostatectomy is commonly believed not to achieve the eradication of locally advanced disease. This retrospective study aimed to elucidate the role of radical prostatectomy in this condition.Methods: A retrospective study of 158 patients surgically treated for clinical stage T3N0M0 prostate cancer was undertaken. Thirty patients had postoperative hormonal treatment, rendering prostate–specific antigen (PSA) follow–up unreliable, and were considered to be progressive at 1 month. Eighteen other patients received postoperative radiotherapy. One hundred and ten patients had radical prostatectomy only. PSA–relapse–free survival was analyzed. The mean follow–up time was 30 months.Results: Seventy–nine percent of the resected specimens were pathologically T3 (pT3), and about 25% were pT3c. Thirteen percent were pT2 and 8% were pT4. Ninety–five specimens (60%) had positive surgical margins. There was poor accordance between the biopsy Gleason score and that of the specimen. A multivariate analysis showed that seminal vesicle and nodal invasion, margin status and a PSA level above 10 ng/ml were independent prognostic factors. In 47 cT3a patients with PSA <10 ng/ml, the PSA–free survival rate exceeded 70% at 24 months and the 5–year estimated PSA–free survival rate was more than 60%.Conclusions: Radical prostatectomy has a place in the treatment of clinical stage T3 prostate cancer patients with a PSA value lower than 10 ng/ml. There is a need to definitively rule out nodal or seminal vesicle invasion in order to select those patients that can benefit from surgery.

Keywords:
Prostate cancer, Locally advanced, Radical prostatectomy
1.
Hodgson D, Warde P, Gospodarowicz M: The management of locally advanced prostate cancer. Urol Oncol 1998;4:3–12.
2.
Fallon B, Williams RD: Current options in the management of clinical stage C prostatic carcinoma. Urol Clin North Am 1990;17:853–866.
3.
Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337: 295–300.
4.
Theiss M, Langer W, Hofmockel G, Frohmüller H: Radikale Prostatektomie als primäre Monotherapie bei kapselüberschreitendem Prostatkarzinom, 15–Jahre–Ergebnisse. Urologe A 1997;36:343–347.
5.
van den Ouden D, Hop W, Schröder FH: Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998;160:1392–1397.
6.
Lerner SE, Blute ML, Zincke H: Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: Outcome and contemporary mobidity. J Urol 1995;154: 1447–1452.
7.
Gerber GS, Thisted RA, Chodak GW, Schröder FH, Frohmüller HG, Scardino PT, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr, Ohori M, Theiss M, Schellhammer PF: Results of radical prostatectomy in men with locally advanced prostate cancer: Multi–institutional pooled analysis. Eur Urol 1997;32:385–390.
8.
Catalona WJ, Smith DS: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate–term results. J Urol 1998;160: 2428–2434.
9.
Thompson IM, Paradelo JC, Crawford ED, Coltman CA, Blumenstein B: An opportunity to determine optimal treatment of pT3 prostatec cancer: The window may be closing. Urology 1994;44:804–811.
10.
Bolla M, Van Poppel H: Phase III study of postoperative external radiotherapy in pathological stage T3N0 prostatic carcinoma. EORTC trial 22911.
11.
Hermanek P, Sobin LH (eds): TNM Classification of Malignant Tumours, ed 4, revision 2. New York, Springer, 1992.
12.
Van Poppel H, Ameye F, Oyen R, Van de Voorde W, Baet L: Accuracy of combined computerized tomography and fine needle aspiration cytology in lymph node staging of localized prostatic carcinoma. J Urol 1994; 151:1310–1314.
13.
Schellhammer PF, Lynch DF: Are monotherapy options reasonable for T3 prostate cancer? Semin Urol Oncol 1997;15:207–214.
14.
Partin AW, Pound CR, Clemens JQ, Epstein JL, Walsh PC: Serum PSA after anatomic radical prostatectomy. The John Hopkins experience after 10 years. Urol Clin North Am 1993; 20:713–725.
15.
Morgan WR, Bergstrahl EJ, Zincke H: Long–term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 1993;41:113–120.
16.
Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152:1843–1849.
17.
Epstein JI, Pound CR, Partin AW, Walsh PC: Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol 1998;160:97–101.
18.
Debras B, Guillonneau B, Bougaran J, Chambon E, Vallancien G: Prognostic significance of seminal vesicle invasion on the radical prostatectomy specimen. Rationale for seminal vesicle biopsies. Eur Urol 1998;33:271–277.
19.
Ravery V, Boccon–Gibod L: T3 prostate cancer: How reliable is clinical staging? Semin Urol Oncol 1997;15:202–206.
20.
Ikonen S, Kärkkäinen P, Kivisaari L, Salo JO, Taari K, Vehmas T, Tervahartiala P, Rannikko S: Magnetic resonance imaging of clinically localized prostatic cancer. J Urol 1998;159: 915–919.
21.
Partin AW, Kattan MW, Subong ENP, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD: Combination of prostate–specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997;277:1445–1451.
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.